Your session is about to expire
← Back to Search
INCB081776 + INCMGA00012 for Cancer
Study Summary
This trial is testing a new cancer drug and its potential side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am currently on medication for an infection.I am 18 or older with advanced cancer and have tried or can't tolerate standard treatments.I have a serious heart condition.I have an autoimmune disease that needed treatment in the last 2 years.I haven't taken vitamin K, steroids, live vaccines, or cancer drugs recently.I agree to have two biopsies of my tumor, one now and one during treatment.My cancer is one of the specified types and is advanced or has spread.I have had one PD-1/L1 treatment and my cancer got worse, or I haven't had PD-1/L1 treatment but my cancer progressed after standard treatments.My AML has returned or didn't respond to treatment, but it's not type M3 or caused by previous therapy.My brain cancer has not been treated or is getting worse despite treatment.I still have side effects from previous treatments or surgeries that are not mild.I have been diagnosed with HIV.I have experienced severe side effects from previous immunotherapy.My cancer type matches one of the specified groups for the study.I have a history of eye retina disease.
- Group 1: INCB081776
- Group 2: INCB081776 + INCMGA00012
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current sample size of this experiment?
"This medical trial necessitates the participation of 140 qualified patients, who can attend one of two locations: Dana Farber Cancer Institute in Hackensack, New jersey or at Hackensack University Medical Center in Houston, Texas."
Is there any precedent for the utilization of INCB081776 in scientific research?
"Presently, 26 medical trials are being conducted to explore the effects of INCB081776. Three of these live studies have reached Phase 3. Although most investigations regarding this medication take place in A CORU�A and Virginia, there are 810 sites conducting research on its efficacy."
Is this a revolutionary clinical trial?
"Research on INCB081776 has been conducted since 2016, when Incyte Corporation sponsored the first trial with 325 participants. Following successful completion of this phase 1 study, it was approved for use in clinical settings and today 26 trials are active across 117 cities and 43 nations."
Has the drug INCB081776 been given regulatory authorization by the FDA?
"With limited evidence of INCB081776's safety and efficacy, our team at Power has assigned a score of 1 to this medication."
What is the ultimate goal of this clinical research?
"According to the Incyte Corporation, which sponsors this trial, the primary objective is measuring treatment-emergent adverse events (TEAEs) over a Screening through 90 days after end of treatment period. Secondary objectives include examining Cmax, t½ and Vz/F for INCB081776."
In what locations is this clinical study taking place?
"This medical trial is being conducted at multiple locations, including the Dana Farber Cancer Institute in Hackensack, New jersey; Hackensack University Medical Center in Houston, Texas; and Md Anderson Cancer Centre in Madison Wisconsin. In addition to these three sites, there are an additional 9 participating clinics."
Is this trial available to participants at the present moment?
"Clinicaltrials.gov indicates that this trial is actively recruiting, having been first posted on August 27th 2018 and updated most recently on November 10th 2022."
Share this study with friends
Copy Link
Messenger